Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

80.78 +3.58 (+4.64%)
Streaming Delayed Price Updated: 2:45 PM EDT, Apr 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
3 Russell 2000 Stocks We Steer Clear Of
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
News headline image
ANI Pharma Insider Sells 4,772 Shares as Revenue Hits $883 Million in 2025 ↗
Specializing in branded and generic pharmaceuticals, this sector player reported a notable insider sale amid a stable transaction pattern. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Reasons ANIP is Risky and 1 Stock to Buy Instead
What a brutal six months it’s been for ANI Pharmaceuticals. The stock has dropped 22.2% and now trades at $73.90, rattling many shareholders. This may have i... 
Via StockStory
Topics Supply Chain
News headline image
2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Question
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Surges 12% After Q4 Earnings Beat ↗
Via Chartmill
News headline image
Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Profitable Stocks That Concern Us
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Generic Pharmaceuticals Q4 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Simply the Best
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including ANI Pharmaceutica... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. 
Via StockStory
Topics Economy Stocks
News headline image
ANI Pharma (ANIP) Q4 2025 Earnings Call Transcript ↗
ANI Pharma (ANIP) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
ANI Pharmaceuticals (NASDAQ:ANIP) Beats Expectations in Strong Q4 CY2025, Stock Jumps 12.4%
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2025, with sales up 29.6% year on year to $247.1 million. The company’s full-year... 
Via StockStory
News headline image
1 Safe-and-Steady Stock Worth Your Attention and 2 That Underwhelm
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
3 Small-Cap Stocks That Fall Short
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
1 Cash-Producing Stock on Our Buy List and 2 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Topics Supply Chain
News headline image
3 Value Stocks with Questionable Fundamentals
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) fell 3.3% in the morning session after investors appeared to take profits as the company announced strong preliminary 2025... 
Via StockStory
News headline image
Stocks making big moves yesterday: OneMain, Nextpower, ANI Pharmaceuticals, Akamai Technologies, and Lemonade
Check out the companies making headlines yesterday: 
Via StockStory
News headline image
Why ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 13.6% in the afternoon session after the company provided strong 2026 financial guidance that surpassed analyst... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 That Underwhelm
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
News headline image
3 Reasons to Avoid ANIP and 1 Stock to Buy Instead
Since January 2021, the S&P 500 has delivered a total return of 83.6%. But one standout stock has nearly doubled the market - over the past five years, ANI Pharmaceuticals has surged 147% to $77.55 per... 
Via StockStory
Topics Stocks Supply Chain
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 15.6% over... 
Via StockStory
Topics Stocks
News headline image
3 Small-Cap Stocks We’re Skeptical Of
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
1 Russell 2000 Stock to Consider Right Now and 2 We Avoid
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
News headline image
The 5 Most Interesting Analyst Questions From ANI Pharmaceuticals’s Q3 Earnings Call
ANI Pharmaceuticals delivered a third quarter marked by substantial year-over-year growth, with management attributing performance to strong momentum across its Rare Disease and Generics segments. CEO... 
Via StockStory
Topics Earnings
News headline image
Generic Pharmaceuticals Stocks Q3 Recap: Benchmarking ANI Pharmaceuticals (NASDAQ:ANIP)
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
The Bancorp: Building the Pulse of Digital Finance One Partnership at a Time ↗
The Bancorp: Building the Pulse of Digital Finance One Partnership at a Time 
Via The Motley Fool
News headline image
ANIP Q3 Deep Dive: Rare Disease Momentum and Generics Expansion Drive Upgraded Outlook
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 53.6% year on year to $227.8 million. The... 
Via StockStory
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.